JPWO2023046135A5 - - Google Patents
Info
- Publication number
- JPWO2023046135A5 JPWO2023046135A5 JP2024518761A JP2024518761A JPWO2023046135A5 JP WO2023046135 A5 JPWO2023046135 A5 JP WO2023046135A5 JP 2024518761 A JP2024518761 A JP 2024518761A JP 2024518761 A JP2024518761 A JP 2024518761A JP WO2023046135 A5 JPWO2023046135 A5 JP WO2023046135A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- membered
- haloc
- stereoisomer
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2021/120863 | 2021-09-27 | ||
| CN2021120863 | 2021-09-27 | ||
| CNPCT/CN2022/081601 | 2022-03-18 | ||
| CN2022081601 | 2022-03-18 | ||
| CNPCT/CN2022/102280 | 2022-06-29 | ||
| CN2022102280 | 2022-06-29 | ||
| CN2022120205 | 2022-09-21 | ||
| CNPCT/CN2022/120205 | 2022-09-21 | ||
| PCT/CN2022/121202 WO2023046135A1 (en) | 2021-09-27 | 2022-09-26 | Polycyclic fused ring derivatives and use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024534610A JP2024534610A (ja) | 2024-09-20 |
| JP2024534610A5 JP2024534610A5 (https=) | 2025-09-16 |
| JPWO2023046135A5 true JPWO2023046135A5 (https=) | 2025-09-16 |
Family
ID=85720111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024518761A Pending JP2024534610A (ja) | 2021-09-27 | 2022-09-26 | 多環式縮合環誘導体およびその利用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250034166A1 (https=) |
| EP (1) | EP4408851A4 (https=) |
| JP (1) | JP2024534610A (https=) |
| KR (1) | KR20240070619A (https=) |
| CN (1) | CN118019746A (https=) |
| WO (1) | WO2023046135A1 (https=) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210006356A (ko) | 2018-04-04 | 2021-01-18 | 아비나스 오퍼레이션스, 인코포레이티드 | 단백질분해 조절제 및 연관된 사용 방법 |
| CN114867726B (zh) | 2019-10-28 | 2023-11-28 | 默沙东有限责任公司 | Kras g12c突变体的小分子抑制剂 |
| US12479834B2 (en) | 2019-11-29 | 2025-11-25 | Taiho Pharmaceutical Co., Ltd. | Phenol compound or salt thereof |
| TW202400170A (zh) | 2022-05-19 | 2024-01-01 | 美商建南德克公司 | 氮雜－四環氧氮呯化合物及其用途 |
| MA71388A (fr) * | 2022-07-05 | 2025-04-30 | Pfizer Inc. | Composés pyrido[4,3-d]pyrimidines |
| WO2024015262A1 (en) * | 2022-07-09 | 2024-01-18 | Blossomhill Therapeutics, Inc. | Fused ring kras inhibitors for treating disease |
| CA3261681A1 (en) | 2022-08-05 | 2024-02-08 | Kumquat Biosciences Inc. | HETEROCYCLIC COMPOUNDS AND THEIR USES |
| WO2024032703A1 (en) * | 2022-08-11 | 2024-02-15 | Beigene, Ltd. | Heterocyclic compounds, compositions thereof, and methods of treatment therewith |
| TW202408512A (zh) * | 2022-08-12 | 2024-03-01 | 大陸商正大天晴藥業集團股份有限公司 | 三環類化合物及其醫藥用途 |
| WO2024041573A1 (en) * | 2022-08-25 | 2024-02-29 | Zai Lab (Shanghai) Co., Ltd. | Fused multi-heterocyclic compounds as kras g12d modulators and uses thereof |
| WO2024112654A1 (en) | 2022-11-21 | 2024-05-30 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| KR20250120376A (ko) * | 2022-12-07 | 2025-08-08 | 자코바이오 파마슈티칼스 컴퍼니 리미티드 | 축합환 화합물 및 이의 응용 |
| CN121419983A (zh) | 2023-01-26 | 2026-01-27 | 阿尔维纳斯运营股份有限公司 | 基于小脑蛋白的kras降解protac及其相关用途 |
| WO2024178304A1 (en) * | 2023-02-24 | 2024-08-29 | Alterome Therapeutics, Inc. | Kras modulators |
| EP4687905A1 (en) | 2023-03-30 | 2026-02-11 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| WO2024209339A1 (en) | 2023-04-05 | 2024-10-10 | Pfizer Inc. | Pyrido[4,3-d]pyrimidine compounds |
| WO2024208305A1 (zh) * | 2023-04-07 | 2024-10-10 | 江苏恒瑞医药股份有限公司 | 稠合四环类化合物、其制备方法及其在医药上的应用 |
| WO2024213979A1 (en) * | 2023-04-10 | 2024-10-17 | Pfizer Inc. | Pyrido[4,3-d]pyrimidine compounds |
| CN120882725A (zh) * | 2023-04-11 | 2025-10-31 | 吉利德科学公司 | Kras调节化合物 |
| WO2024218686A1 (en) * | 2023-04-20 | 2024-10-24 | Pfizer Inc. | Pyrido[4,3-d]pyrimidine compounds |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| EP4713330A1 (en) * | 2023-05-16 | 2026-03-25 | HUTCHMED Limited | Tricyclic compounds and uses thereof |
| WO2025006783A2 (en) * | 2023-06-30 | 2025-01-02 | Merck Patent Gmbh | Heterobifunctional compounds for the degradation of kras |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| AU2024323424A1 (en) | 2023-08-17 | 2026-03-05 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| WO2025049619A1 (en) | 2023-08-29 | 2025-03-06 | Quanta Therapeutics, Inc. | Kras modulators and uses thereof |
| AU2024337913A1 (en) | 2023-09-08 | 2026-03-26 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| TW202528315A (zh) | 2023-09-21 | 2025-07-16 | 美商樹線生物科學公司 | 螺環二氫哌喃并吡啶ＫＲａｓ抑制劑 |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025085748A1 (en) * | 2023-10-20 | 2025-04-24 | Merck Sharp & Dohme Llc | Small molecule inhibitors of kras proteins |
| CN117700374A (zh) * | 2023-12-25 | 2024-03-15 | 吉尔多肽生物制药(大连市)有限公司 | 手性高吗啉-3-甲酸的制备方法 |
| WO2025148868A1 (zh) * | 2024-01-08 | 2025-07-17 | 泰励生物科技（上海）有限公司 | 一种抗体偶联药物及其用途 |
| WO2025168072A1 (en) * | 2024-02-08 | 2025-08-14 | Beigene (Suzhou) Co., Ltd. | Heterocyclic compounds, compositions thereof, and methods of treatment therewith |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025245127A1 (en) | 2024-05-21 | 2025-11-27 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026035945A1 (en) | 2024-08-07 | 2026-02-12 | Tesseract Medicines Us, Llc | Covalent-induced drug conjugates targeting kras and comprising a topoisomerase payload |
| WO2026035947A1 (en) | 2024-08-07 | 2026-02-12 | Tesseract Medicines Us, Llc | Kras-targeting covalent-induced drug conjugates comprising a topoisomerase payload |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026064527A1 (en) | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload |
| WO2026064520A1 (en) | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5962453A (en) * | 1995-08-08 | 1999-10-05 | Nippon Shinyaku Co. Ltd. | Triazine derivative and medicine |
| KR20080036957A (ko) * | 2005-06-23 | 2008-04-29 | 아스트라제네카 아베 | 위장 질환 치료용 뉴로키닌 수용체 길항제로서의 신규한아제티딘 유도체 |
| CN102875556B (zh) * | 2011-07-12 | 2016-03-30 | 天津药明康德新药开发有限公司 | (4s)-1-取代-2,5-二氮杂双环[2,2,1]庚烷衍生物及制备方法 |
| US9181288B2 (en) * | 2014-01-16 | 2015-11-10 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| WO2018206539A1 (en) * | 2017-05-11 | 2018-11-15 | Astrazeneca Ab | Heteroaryl compounds that inhibit g12c mutant ras proteins |
| TW202012415A (zh) * | 2018-05-08 | 2020-04-01 | 瑞典商阿斯特捷利康公司 | 化學化合物 |
| MX2022001421A (es) * | 2019-08-02 | 2022-06-08 | Shanghai Jemincare Pharmaceuticals Co Ltd | Compuesto tetracíclico, método de preparación y uso del mismo. |
| CN112390818B (zh) * | 2019-08-12 | 2023-08-22 | 劲方医药科技(上海)有限公司 | 取代的杂芳环并二氢嘧啶酮衍生物，其制法与医药上的用途 |
| EP4065231A1 (en) * | 2019-11-27 | 2022-10-05 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| CA3210167A1 (en) * | 2021-02-09 | 2022-08-18 | Genentech, Inc. | Tetracyclic oxazepine compounds and uses thereof |
| WO2022188729A1 (en) * | 2021-03-07 | 2022-09-15 | Jacobio Pharmaceuticals Co., Ltd. | Fused ring derivatives useful as kras g12d inhibitors |
| EP4310091A4 (en) * | 2021-03-17 | 2025-04-16 | Genfleet Therapeutics (Shanghai) Inc. | Pyrimidine-fused cyclic compound, preparation method therefor and use thereof |
| CN116113632B (zh) * | 2021-03-30 | 2025-08-29 | 浙江海正药业股份有限公司 | 杂环类衍生物、其制备方法及其医药上的用途 |
| CN117255793A (zh) * | 2021-06-21 | 2023-12-19 | 江苏恒瑞医药股份有限公司 | 稠合四环类化合物、其制备方法及其在医药上的应用 |
-
2022
- 2022-09-26 CN CN202280065503.XA patent/CN118019746A/zh active Pending
- 2022-09-26 US US18/695,384 patent/US20250034166A1/en active Pending
- 2022-09-26 WO PCT/CN2022/121202 patent/WO2023046135A1/en not_active Ceased
- 2022-09-26 JP JP2024518761A patent/JP2024534610A/ja active Pending
- 2022-09-26 EP EP22872179.1A patent/EP4408851A4/en active Pending
- 2022-09-26 KR KR1020247013592A patent/KR20240070619A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2023046135A5 (https=) | ||
| RU2309951C2 (ru) | Производные никотинамида, способы их получения, фармацевтическая композиция на их основе и применение | |
| JP2020517616A5 (https=) | ||
| RU2413727C2 (ru) | Производные пиразола и их применение в качестве ингибиторов рецепторных тирозинкиназ | |
| JP2021519783A5 (https=) | ||
| ES2566482T3 (es) | Derivados de oxazol sustituidos, composición farmacéutica que contiene los derivados, y método para tratar la enfermedad de Parkinson utilizando los mismos | |
| JP2020533277A5 (https=) | ||
| RU2013156074A (ru) | Диазакарбазолы и способы применения | |
| RU2013137653A (ru) | Замещенное фосфоросодержащей группой хинолиноподобное соединение, способ его получения, лекарственная композиция, содержащая это соединение, и его применение | |
| JP2011506494A5 (https=) | ||
| AR073548A1 (es) | Compuestos derivados de diazol y triazol, composiciones y uso de los mismos para modular los niveles de acido urico | |
| RU2012103492A (ru) | Содержащие фосфор соединения хиназолина и способы применения | |
| JPWO2021081212A5 (https=) | ||
| RU2011103434A (ru) | Изоиндолоны и способы их применения | |
| RU2011103454A (ru) | Бициклические гетероциклы в качестве ингибиторов киназы мек | |
| RU2009105826A (ru) | 2,4-ди(ариламино)питимидин-5-карбоксамидные соединения в качестве ингибиторов jak-киназ | |
| JP2017526636A5 (https=) | ||
| JPWO2022223025A5 (https=) | ||
| RU2008112691A (ru) | Азотсодержащее гетероциклическое соединение и его фармацевтическое применение | |
| JPWO2021000935A5 (https=) | ||
| RU2007147346A (ru) | Новые производные 2-азетидинона в качестве ингибиторов всасывания холестерина для лечения гиперлипидемических состояний | |
| JPWO2023018864A5 (https=) | ||
| JP2020516616A5 (https=) | ||
| JPWO2020219650A5 (https=) | ||
| JPWO2023016434A5 (https=) |